Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: Correlation with virus-like particle IgG concentration

Janine T. Bryan, Kathrin U. Jansen, Robert S. Lowe, Kenneth Fife, Tracy McClowry, Dessa Glass, Darron Brown

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Neutralization of virus is likely to be necessary for development of an effective prophylactic vaccine against genital human papillomavirus (HPV) infection. Two New Zealand white rabbits were immunized with purified HPV type 11 (HPV 11) virions in Freund's adjuvant. An enzyme linked immunoassay (ELISA) was used to determine the quantity of IgG which recognized the HPV 11 major capsid protein (L1 protein) virus-like particles (VLPs) in the two anti-HPV 11 sera (serum A and serum B). The concentration of HPV 11 L1 VLP- specific IgG in the A and B sera were determined to be 37 and 90 υg per ml, respectively. The A and B sera were used in neutralization experiments in the athymic mouse xenograft system with known quantities of purified HPV 11 virions. The concentration of HPV 11 L1 VLP-specific IgG required to neutralize HPV 11 was determined for each antiserum. This concentration of IgG was approximately 700 to 900 ng per ml. This study demonstrates a positive correlation between the level of HPV 11 L1 VLP-specific IgG in animals immunized with HPV 11 virions and neutralization of HPV 11 in the athymic mouse model. Further studies are needed 1) to determine if sera or genital secretions from other species are neutralizing in the athymic mouse xenograft system, and 2) to determine if the VLP ELISA can be used as a reliable substitute for more cumbersome neutralization assays.

Original languageEnglish
Pages (from-to)185-188
Number of pages4
JournalJournal of Medical Virology
Volume53
Issue number3
DOIs
StatePublished - Nov 1997

Fingerprint

Human papillomavirus 11
Heterografts
Nude Mice
Virion
Immunoglobulin G
Serum
Immunoenzyme Techniques
Papillomavirus Infections
Freund's Adjuvant
Capsid Proteins
Immune Sera
Vaccines

Keywords

  • Anti-body neutralization
  • Athymic mice
  • Human papilloma-virus

ASJC Scopus subject areas

  • Virology

Cite this

Human papillomavirus type 11 neutralization in the athymic mouse xenograft system : Correlation with virus-like particle IgG concentration. / Bryan, Janine T.; Jansen, Kathrin U.; Lowe, Robert S.; Fife, Kenneth; McClowry, Tracy; Glass, Dessa; Brown, Darron.

In: Journal of Medical Virology, Vol. 53, No. 3, 11.1997, p. 185-188.

Research output: Contribution to journalArticle

Bryan, Janine T. ; Jansen, Kathrin U. ; Lowe, Robert S. ; Fife, Kenneth ; McClowry, Tracy ; Glass, Dessa ; Brown, Darron. / Human papillomavirus type 11 neutralization in the athymic mouse xenograft system : Correlation with virus-like particle IgG concentration. In: Journal of Medical Virology. 1997 ; Vol. 53, No. 3. pp. 185-188.
@article{612c8931f10243eea0a22aeb2a2839b0,
title = "Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: Correlation with virus-like particle IgG concentration",
abstract = "Neutralization of virus is likely to be necessary for development of an effective prophylactic vaccine against genital human papillomavirus (HPV) infection. Two New Zealand white rabbits were immunized with purified HPV type 11 (HPV 11) virions in Freund's adjuvant. An enzyme linked immunoassay (ELISA) was used to determine the quantity of IgG which recognized the HPV 11 major capsid protein (L1 protein) virus-like particles (VLPs) in the two anti-HPV 11 sera (serum A and serum B). The concentration of HPV 11 L1 VLP- specific IgG in the A and B sera were determined to be 37 and 90 υg per ml, respectively. The A and B sera were used in neutralization experiments in the athymic mouse xenograft system with known quantities of purified HPV 11 virions. The concentration of HPV 11 L1 VLP-specific IgG required to neutralize HPV 11 was determined for each antiserum. This concentration of IgG was approximately 700 to 900 ng per ml. This study demonstrates a positive correlation between the level of HPV 11 L1 VLP-specific IgG in animals immunized with HPV 11 virions and neutralization of HPV 11 in the athymic mouse model. Further studies are needed 1) to determine if sera or genital secretions from other species are neutralizing in the athymic mouse xenograft system, and 2) to determine if the VLP ELISA can be used as a reliable substitute for more cumbersome neutralization assays.",
keywords = "Anti-body neutralization, Athymic mice, Human papilloma-virus",
author = "Bryan, {Janine T.} and Jansen, {Kathrin U.} and Lowe, {Robert S.} and Kenneth Fife and Tracy McClowry and Dessa Glass and Darron Brown",
year = "1997",
month = "11",
doi = "10.1002/(SICI)1096-9071(199711)53:3<185::AID-JMV1>3.0.CO;2-4",
language = "English",
volume = "53",
pages = "185--188",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Human papillomavirus type 11 neutralization in the athymic mouse xenograft system

T2 - Correlation with virus-like particle IgG concentration

AU - Bryan, Janine T.

AU - Jansen, Kathrin U.

AU - Lowe, Robert S.

AU - Fife, Kenneth

AU - McClowry, Tracy

AU - Glass, Dessa

AU - Brown, Darron

PY - 1997/11

Y1 - 1997/11

N2 - Neutralization of virus is likely to be necessary for development of an effective prophylactic vaccine against genital human papillomavirus (HPV) infection. Two New Zealand white rabbits were immunized with purified HPV type 11 (HPV 11) virions in Freund's adjuvant. An enzyme linked immunoassay (ELISA) was used to determine the quantity of IgG which recognized the HPV 11 major capsid protein (L1 protein) virus-like particles (VLPs) in the two anti-HPV 11 sera (serum A and serum B). The concentration of HPV 11 L1 VLP- specific IgG in the A and B sera were determined to be 37 and 90 υg per ml, respectively. The A and B sera were used in neutralization experiments in the athymic mouse xenograft system with known quantities of purified HPV 11 virions. The concentration of HPV 11 L1 VLP-specific IgG required to neutralize HPV 11 was determined for each antiserum. This concentration of IgG was approximately 700 to 900 ng per ml. This study demonstrates a positive correlation between the level of HPV 11 L1 VLP-specific IgG in animals immunized with HPV 11 virions and neutralization of HPV 11 in the athymic mouse model. Further studies are needed 1) to determine if sera or genital secretions from other species are neutralizing in the athymic mouse xenograft system, and 2) to determine if the VLP ELISA can be used as a reliable substitute for more cumbersome neutralization assays.

AB - Neutralization of virus is likely to be necessary for development of an effective prophylactic vaccine against genital human papillomavirus (HPV) infection. Two New Zealand white rabbits were immunized with purified HPV type 11 (HPV 11) virions in Freund's adjuvant. An enzyme linked immunoassay (ELISA) was used to determine the quantity of IgG which recognized the HPV 11 major capsid protein (L1 protein) virus-like particles (VLPs) in the two anti-HPV 11 sera (serum A and serum B). The concentration of HPV 11 L1 VLP- specific IgG in the A and B sera were determined to be 37 and 90 υg per ml, respectively. The A and B sera were used in neutralization experiments in the athymic mouse xenograft system with known quantities of purified HPV 11 virions. The concentration of HPV 11 L1 VLP-specific IgG required to neutralize HPV 11 was determined for each antiserum. This concentration of IgG was approximately 700 to 900 ng per ml. This study demonstrates a positive correlation between the level of HPV 11 L1 VLP-specific IgG in animals immunized with HPV 11 virions and neutralization of HPV 11 in the athymic mouse model. Further studies are needed 1) to determine if sera or genital secretions from other species are neutralizing in the athymic mouse xenograft system, and 2) to determine if the VLP ELISA can be used as a reliable substitute for more cumbersome neutralization assays.

KW - Anti-body neutralization

KW - Athymic mice

KW - Human papilloma-virus

UR - http://www.scopus.com/inward/record.url?scp=0031428438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031428438&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-9071(199711)53:3<185::AID-JMV1>3.0.CO;2-4

DO - 10.1002/(SICI)1096-9071(199711)53:3<185::AID-JMV1>3.0.CO;2-4

M3 - Article

C2 - 9365880

AN - SCOPUS:0031428438

VL - 53

SP - 185

EP - 188

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 3

ER -